https://www.taxtmi.com/caselaws?id=81497 Cisplatin Injection was examined for central excise classification and exemption treatment. The product was held not to be a patent or proprietary medicine under Tariff Item 14E because the labels showed only the product name, strength, and manufacturer details, without any brand name, trade mark, monogram, or other proprietary mark indicating trade connection. It was therefore placed under Tariff Item 68. On exemption, the product was treated as eligible under Notification No. 234/82-C.E. as a bulk drug medicine because it conformed to pharmacopoeial standards, was used in cancer treatment, and later appeared in the United States Pharmacopoeia XXII 1990. en-us Thu, 29 Aug 1991 00:00:00 +0530 Mon, 27 Jun 2011 11:20:15 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=81497 Cisplatin Injection was examined for central excise classification and exemption treatment. The product was held not to be a patent or proprietary medicine under Tariff Item 14E because the labels showed only the product name, strength, and manufacturer details, without any brand name, trade mark, monogram, or other proprietary mark indicating trade connection. It was therefore placed under Tariff Item 68. On exemption, the product was treated as eligible under Notification No. 234/82-C.E. as a bulk drug medicine because it conformed to pharmacopoeial standards, was used in cancer treatment, and later appeared in the United States Pharmacopoeia XXII 1990. Case-Laws Central Excise Thu, 29 Aug 1991 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=81497